Compare Incyte Corporation (INCY) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Match Group Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Match Group Inc trades at $39.02 (market cap $9.10B). The key difference: Incyte Corporation is far larger — about 2.5× Match Group Inc's market cap, and Match Group Inc pays a 2.05% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MTCH | |
|---|---|---|
Market Cap | $23.11B | $9.10B |
Sector | Health | Media |
52-Week High | $118.52 | $40.29 |
52-Week Low | $67.38 | $28.90 |
Enterprise Value | $19.13B | $12.05B |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
MTCH trades at $39.10, down 0.13% today, with a bullish technical outlook supported by moving averages and key resistance at $40. The company reported Q1 2026 revenue growth of 4% but missed EPS expectations. Strong profitability is evident with a 73.8% gross margin and 17.59% net margin. Recent news highlights Tinder's turnaround efforts and Hinge's growth, with Q2 2026 earnings due August 4, 2026.
The stock presents a moderate buy opportunity with a consensus price target of $41.63, offering ~6% upside. Risks include Tinder's user declines and high debt levels, but valuation multiples like a P/E of 14.94 suggest potential undervaluation. Investor sentiment is positive, with no analyst sell ratings, though execution on user growth remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
